UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients

American journal of infection control, 2013-12, Vol.41 (12), p.1249-1252

2013

Volltextzugriff (PDF)

Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphoma

Diagnostic pathology, 2022-10, Vol.17 (1), p.1-84, Article 84

2022

Volltextzugriff (PDF)

Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma

Diagnostic pathology, 2022-08, Vol.17 (1), p.1-63, Article 63

2022

Volltextzugriff (PDF)

Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm

The New England journal of medicine, 2018-10, Vol.379 (15), p.1479-1481

2018

Volltextzugriff (PDF)

Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era

Open forum infectious diseases, 2021-07, Vol.8 (7), p.ofab353-ofab353

2021

Volltextzugriff (PDF)

Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study

Clinical infectious diseases, 2021-08, Vol.73 (3), p.e815-e821

2021

Volltextzugriff (PDF)

Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need

Blood reviews, 2023-07, Vol.60, p.101095-101095, Article 101095

2023

Volltextzugriff (PDF)

Multifocal Necrotizing Leukoencephalopathy With Preferential Microglia Toxicity in a Patient Treated With Chimeric Antigen Receptor T-Cells and Review of the Literature

Journal of neuropathology and experimental neurology, 2020-10, Vol.79 (10), p.1115-1121

2020

Volltextzugriff (PDF)

Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen

Psycho-oncology (Chichester, England), 2018-01, Vol.27 (1), p.354-358

2018

Volltextzugriff (PDF)

Intensive induction chemotherapy vs hypomethylating agent–based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia

Hematological oncology, 2018-04, Vol.36 (2), p.495-497

2018

Volltextzugriff (PDF)

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

The New England journal of medicine, 2022-07, Vol.387 (2), p.132-147

2022

Volltextzugriff (PDF)

Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones

Science (American Association for the Advancement of Science), 1992-07, Vol.257 (5067), p.238-241

1992

Volltextzugriff (PDF)

More on Blastic Plasmacytoid Dendritic-Cell Neoplasms

The New England journal of medicine, 2019-02, Vol.380 (7), p.695-697

2019

Volltextzugriff (PDF)

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8009-8009

2023

Volltextzugriff (PDF)

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8029-8029

2022

Volltextzugriff (PDF)

Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8028-8028

2022

Volltextzugriff (PDF)

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood, 2023-11, Vol.142 (Supplement 1), p.4762-4762

2023

Volltextzugriff (PDF)

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8013-8013

2021

Volltextzugriff (PDF)

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8005-8005

2021

Volltextzugriff (PDF)

Biomarker Correlates of 3 Year Response in Cartitude-1: A Phase 1b/2 Open-Label Study of Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S377-S377

2024

Volltextzugriff (PDF)

Hematopoietic cell transplantation for refractory acute myeloid leukemia

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7059-7059

2013

Volltextzugriff (PDF)

Mitoxantrone and etoposide for acute myeloid leukemia in first relapse

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.6563-6563

2012

Volltextzugriff (PDF)

Single Agent Gemtuzumab Ozogamicin (Mylotarg) Can Induce Hematologic Remissions in Patients with Refractory Acute Myelogenous Leukemia (AML) Relapse Following Allogeneic Stem Cell Transplantation but May Precipitate Acute Graft-Versus-Host Disease (GVHD)

Blood, 2005-11, Vol.106 (11), p.5405-5405

2005

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(40)
Berichte
(1)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Humans
(12)
Middle Aged
(6)
Female
(5)
Hematology
(5)
Oncology
(5)
Patients
(5)
Aged
(4)
Bone Marrow
(4)
Cancer
(4)
Infectious Diseases
(4)
Leukemia
(4)
Male
(4)
Tumors
(4)
Acute Myeloid Leukemia
(3)
Aged, 80 And Over
(3)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Immunology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients

Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphoma

Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma

Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm

Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era

Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study

Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need

Multifocal Necrotizing Leukoencephalopathy With Preferential Microglia Toxicity in a Patient Treated With Chimeric Antigen Receptor T-Cells and Review of the Literature

Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen

Intensive induction chemotherapy vs hypomethylating agent–based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones

More on Blastic Plasmacytoid Dendritic-Cell Neoplasms

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B

Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1

Biomarker Correlates of 3 Year Response in Cartitude-1: A Phase 1b/2 Open-Label Study of Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma

Hematopoietic cell transplantation for refractory acute myeloid leukemia

Mitoxantrone and etoposide for acute myeloid leukemia in first relapse

Single Agent Gemtuzumab Ozogamicin (Mylotarg) Can Induce Hematologic Remissions in Patients with Refractory Acute Myelogenous Leukemia (AML) Relapse Following Allogeneic Stem Cell Transplantation but May Precipitate Acute Graft-Versus-Host Disease (GVHD)

Suchergebnisse filtern